Katie Peng
CIK: 0001983850
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Adicet Bio shares positive Phase 1 lupus data, Wedbush lifts target. Adicet Bio announced that its Phase 1 study of Prula‑cel in lupus patients showed positive safety and efficacy signals, and the company is moving forward with plans for a pivotal trial. Wedbush analysts kept an Outperform rating and raised their price target to $28, reflecting confidence in the data. The news comes as the stock trades near its 52‑week high, with analyst consensus targets averaging $34.83.
Transaction History
| SRRK | ▼ Sell | Open Market | 2,988 | $160K | 7/1/2026 | View on chart |
| SRRK | ▼ Sell | Open Market | 21 | $1K | 7/1/2026 | View on chart |
| SRRK | ▼ Sell | Open Market | 2,437 | $132K | 7/1/2026 | View on chart |
| SRRK | ▲ Buy | Grant | 6,839 | $0 | 6/4/2026 | View on chart |
| SRRK | ▼ Sell | Open Market | 726 | $32K | 12/16/2025 | View on chart |
| SRRK | ▼ Sell | Open Market | 280 | $12K | 12/16/2025 | View on chart |
| SRRK | ▼ Sell | Open Market | 930 | $30K | 9/16/2025 | View on chart |
| SRRK | ▼ Sell | Open Market | 76 | $3K | 9/16/2025 | View on chart |
| SRRK | ▼ Sell | Open Market | 2,977 | $95K | 6/16/2025 | View on chart |
| SRRK | ▼ Sell | Open Market | 54 | $2K | 6/16/2025 | View on chart |
| ACET | ▲ Buy | Grant | 5,900 | $0 | 6/11/2025 | View on chart |
| SRRK | ▲ Buy | Grant | 7,632 | $0 | 5/22/2025 | View on chart |
| SRRK | ▼ Sell | Open Market | 1,006 | $35K | 3/17/2025 | View on chart |
| SRRK | ▲ Buy | Grant | 4,500 | $0 | 6/27/2024 | View on chart |
| ACET | ▲ Buy | Grant | 5,900 | $0 | 6/5/2024 | View on chart |
| SRRK | ▲ Buy | Grant | 26,825 | $0 | 4/9/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Scholar Rock Refiles Apitegromab Application With EMA
Scholar Rock has resubmitted its marketing authorization application to the European Medicines Agency for apitegromab, a treatment for spinal muscular atrophy in children and adults. This regulatory step follows the company's recent release of its Q2 2026 financial results. The stock is currently trading near its 52-week low, which provides context for the significance of this regulatory update.
Scholar Rock Refiles Apitegromab Application With EMA. Scholar Rock has resubmitted its marketing authorization application to the European Medicines Agency for apitegromab, a treatment for spinal muscular atrophy in children and adults. This regulatory step follows the company's recent release of its Q2 2026 financial results. The stock is currently trading near its 52-week low, which provides context for the significance of this regulatory update.